Novartis/NVS

-0.08%
-
1D1W1MYTD1YMAX

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Ticker

NVS

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Vasant Narasimhan

Employees

76,057

Headquarters

Basel, Switzerland

Novartis Metrics

BasicAdvanced
US$226B
Market cap
13.91
P/E ratio
US$7.37
EPS
0.58
Beta
US$3.50
Dividend rate
3.65%
Dividend yield
US$226B
0.58245
US$108.78
US$88.86
1.6M
US$3.50
0.903
0.707
47.183
68.547
77.34%
27.767
13.99%
8.82%
19.86%
12.43%
13.913
4.728
5.058
44.08
3.55%
3.41%
3.65%
14.72%
58.09%
-2.21%
5.22%
4.26%

What the Analysts think about Novartis

Analyst Ratings

Majority rating from 9 analysts.
Hold

Price Targets

Average projection from 8 analysts.
11.73% upside
High US$129.00
Low US$106.99
US$102.49
Current price
US$114.51
Average price target

Novartis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
22.17% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$12B
2.92%
Net income
US$2.7B
-68.3%
Profit margin
22.17%
-69.21%

Novartis Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.76%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
US$1.83
US$1.83
US$1.53
US$1.80
-
Expected
US$1.68
US$1.70
US$1.69
US$1.69
US$1.85
Surprise
8.68%
7.86%
-9.2%
6.76%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Novartis stock?

Novartis (NVS) has a market cap of $226B as of May 20, 2024.

What is the P/E ratio for Novartis stock?

The price to earnings (P/E) ratio for Novartis (NVS) stock is 13.91 as of May 20, 2024.

Does Novartis stock pay dividends?

Yes, the Novartis (NVS) stock pays dividends to shareholders. As of May 20, 2024, the dividend rate is $3.4987 and the yield is 3.65%. Novartis has a payout ratio of 77.34% on a trailing twelve-month basis.

When is the next Novartis dividend payment date?

The next Novartis (NVS) dividend payment date is unconfirmed.

What is the beta indicator for Novartis?

Novartis (NVS) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Novartis stock price target?

The target price for Novartis (NVS) stock is $114.51, which is 11.35% above the current price of $102.84. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Novartis stock

Buy or sell Novartis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing